Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis

Author:

Chen Yan1,Huang Hui-Bin2,Peng Jin-Min1,Weng Li1,Du Bin1ORCID

Affiliation:

1. Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

2. Department of Critical Care Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China

Abstract

Ceftazidime-avibactam (CAZ-AVI) has been used as a frontline agent in the treatment of multidrug-resistant (MDR) Gram-negative bacterial infections. However, the efficacy and safety of CAZ-AVI on carbapenem-resistant Enterobacterales (CRE) bloodstream infections (BSIs) remain unclear.

Funder

Beijing Municipal Science and Technology Commission

Chinese Academy of Medical Sciences

Ministry of Science and Technology of the People's Republic of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Reference31 articles.

1. Centers for Disease Control and Prevention. 2015. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE)—November 2015 update CRE toolkit. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf. Accessed December 3 2016.

2. The rapid spread of carbapenem-resistant Enterobacteriaceae

3. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections

4. World Health Organization. 2017. Prioritization of pathogens to guide discovery research and development of new antibiotics for drug-resistant bacterial infections including tuberculosis. https://apps.who.int/iris/handle/10665/311820. Accessed November 5 2021.

5. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3